[{"orgOrder":0,"company":"Tiziana Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tiziana Announces the FDA Allowed Treatment for a Secondary Progressive Multiple Sclerosis Patient for the Nasal Administration of Foralumab","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Tiziana Life Sciences"},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Benlysta Granted Orphan Drug Designation by US FDA For the Potential Treatment of Systemic Sclerosis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"Approved","date":"February 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"GSK"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
A fully human monoclonal antibody, Benlysta (belimumab) inhibits the prolonged survival of B cells induced by increased BLyS, including autoreactive B cells, and reduces the differentiation of B cells into immunoglobulin-producing plasma cells.
Due to Foralumab’s ability to affect systemic immunity through the epithelial lining of the nose, respiratory tract and gut, it is the first antibody that can be dosed nasally or orally.